NCT01932710 is a Phase 2 clinical trial of White Blood Cell Transfusion in Leukemia, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT01932710?

NCT01932710 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT01932710?

Interventions in NCT01932710: White Blood Cell Transfusion.

Is NCT01932710 still recruiting?

NCT01932710 is currently completed. Last updated 12 January 2018.

Last reviewed 2018-01-12 · How we verify

NCT01932710

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Feasibility Study of Prophylactic White Blood Cell Transfusions

Completed Phase 2 Last updated 12 January 2018

What this trial tests

Phase 2 trial testing White Blood Cell Transfusion in Leukemia in 45 participants. Completed in 30 November 2016.

Timeline

20 September 2013

Primary endpoint
30 November 2016

30 November 2016

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	45
Start date	20 September 2013
Primary completion	30 November 2016
Estimated completion	30 November 2016
Sites	1 location across United States

Drugs / interventions tested

White Blood Cell Transfusion

Conditions studied

Leukemia — all drugs for Leukemia →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with leukemia often have low white blood cell counts after chemotherapy, which puts them at greater risk of infection. The standard of care for preventing infections is to give these patients antibiotic, antifungal, and antiviral drugs during the time that white blood cell counts are low. However, many patients still develop infections during chemotherapy. Radiated white blood cell transfusions are a standard treatment once a patient develops a severe infection. The goal of this clinical research study is to learn if giving white blood cell transfusions that are not radiated early in chemotherapy might delay or prevent infections in patients with leukemia. Researchers also want to learn more about the type and severity of any infections that do occur.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Granulocyte transfusions for treating infections in people with neutropenia or neutrophil dysfunction.
Estcourt LJ, Stanworth SJ, Hopewell S, Doree C, et al · · 2016 · cited 43× · PMID 27128488 · DOI 10.1002/14651858.cd005339.pub2
Granulocyte transfusions for preventing infections in people with neutropenia or neutrophil dysfunction.
Estcourt LJ, Stanworth S, Doree C, Blanco P, et al · · 2015 · cited 30× · PMID 26118415 · DOI 10.1002/14651858.cd005341.pub3

Verify or expand the search:

Other recruiting trials for Leukemia

Currently open trials in the same condition.

NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01932710 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 12 January 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01932710.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing